Provided by Tiger Fintech (Singapore) Pte. Ltd.

Shuttle Pharmaceuticals Inc

0.4056
-0.0055-1.34%
Post-market: 0.45050.0449+11.07%19:51 EDT
Volume:304.41K
Turnover:131.12K
Market Cap:2.54M
PE:-0.09
High:0.4900
Open:0.4000
Low:0.4000
Close:0.4111
Loading ...

Shuttle Pharmaceuticals Soars Premarket Following Completion of Phase 2 Glioblastoma Trial Site Enrollment

MT Newswires Live
·
29 Oct 2024

Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update

Dow Jones
·
29 Oct 2024

BRIEF-Shuttle Pharma Completes Clinical Trial Site Enrollment For Phase 2 Of Ropidoxuridine For Treatment Of Patients With Glioblastoma

Reuters
·
29 Oct 2024

Shuttle’s clinical trial site enrollments complete for Phase 2 of IPdR for GBM

TIPRANKS
·
29 Oct 2024

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients With Glioblastoma

THOMSON REUTERS
·
29 Oct 2024

Shuttle Pharmaceuticals Holdings Inc - Trial Expected to Be Completed in 18-24 Months

THOMSON REUTERS
·
29 Oct 2024

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire
·
29 Oct 2024

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

GlobeNewswire
·
28 Oct 2024

Shuttle Pharmaceuticals Launches Equity Offering

MT Newswires Live
·
20 Sep 2024

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients With Glioblastoma

THOMSON REUTERS
·
16 Sep 2024

Shuttle Pharmaceuticals Holdings Inc - Pharma Adds Two Sites for Phase 2 Trial of Ropidoxuridine

THOMSON REUTERS
·
16 Sep 2024

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire
·
16 Sep 2024